Plant Name: Physalis solanaceus
Taxonomic Information:
Plant ID: NPO8671
Plant Latin Name: Physalis solanaceus
Taxonomy Genus: Physalis
Taxonomy Family: Solanaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| NPSR1; | |
| ACHE; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA12; CA7; CA4; | |
| TYR; | |
| ALOX12; HSD17B2; HSD17B10; NOX4; ALOX15; POLB; | |
| AHR; | |
| LMNA; FABP3; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.251E-07 | 3.804E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.051E-07 | 4.230E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.227E-06 | 8.348E-04 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.026E-06 | 1.068E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.059E-06 | 1.068E-03 | ALOX12, AURKB, AXL, CDK1, FFAR4, IGF1R, KDR, LMNA, PIM1 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.026E-06 | 1.068E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 3.026E-06 | 1.430E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1, HSD17B10, HSD17B2, NOX4, TYR |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.086E-06 | 1.430E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 3.278E-06 | 1.487E-03 | ALOX15, AXL, CDK1, CYP1A1, CYP1A2, CYP1B1, KDR |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.565E-06 | 1.528E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 4.738E-06 | 1.842E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.738E-06 | 1.842E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 5.861E-06 | 2.123E-03 | AXL, CYP1A1, CYP1A2, FABP3, FFAR1, FLT3, HSD17B2, TYR |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 6.074E-06 | 2.123E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 6.074E-06 | 2.123E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 6.441E-06 | 2.191E-03 | AXL, FLT3, IGF1R, KDR, MET |
| CC | GO:0016020; membrane | GO:0016020; membrane | 7.492E-06 | 2.435E-03 | ACHE, ALOX12, ALOX15, AXL, CA12, CA4, CDK1, CYP1A1, CYP1A2, CYP1B1, FFAR1, FFAR4, FLT3, HSD17B10, HSD17B2, IGF1R, KDR, LMNA, MET, NOX4, NPSR1, PIM1, TYR |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 8.309E-06 | 2.622E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 8.712E-06 | 2.672E-03 | AHR, ALOX12, CDK1, CYP1B1, FABP3, FLT3, IGF1R, KDR, LMNA, NOX4, PIM1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.214E-05 | 3.477E-03 | CYP1A1, CYP1A2 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.839E-05 | 5.134E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.886E-05 | 5.134E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 2.021E-05 | 5.366E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.330E-05 | 8.147E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.472E-05 | 8.400E-03 | CA12, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 3.584E-05 | 8.576E-03 | ALOX15, AXL, CYP1A1, CYP1B1, FFAR4, FLT3, IGF1R, KDR, NOX4 |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 4.187E-05 | 9.803E-03 | ALOX12, CA12, CA7, FABP3, FFAR1, MET, NOX4, NPSR1 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 4.236E-05 | 9.813E-03 | FLT3, KDR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.581E-20 | 1.402E-17 | CA12, CA1, CA3, CA2, CA5A, CA4, CA7, CA6, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 9.047E-13 | 8.368E-11 | CAMK2B, SRC, MMP2, PIK3R1, HIF1A, MMP9, PTK2, IGF1R, KDR, AKT1, MAPK1, TP53, MET, TLR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 6.112E-12 | 3.769E-10 | GSK3B, FLT3, DAPK1, MMP2, PIK3R1, HIF1A, MMP9, NFKB1, PTK2, IGF1R, AR, AKT1, MAPK1, PPARG, MET, TP53, PPARD |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.722E-10 | 2.117E-08 | CYP2C9, CYP2C8, PLA2G1B, ALOX5, ALOX15, ALOX12, CYP2C19, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 6.730E-11 | 3.112E-09 | CYP2C9, CYP2C8, PLA2G1B, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.049E-09 | 3.235E-08 | HPGD, FLT3, MMP3, PPARG, TP53, MPO, MMP9, MET, NFKB1, PTK2, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.376E-09 | 8.922E-08 | CYP2C9, CYP2C8, MAOA, ALOX5, ALOX15, MAPK1, ALOX12, CYP2C19, PTGS1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.968E-09 | 9.176E-08 | HSD17B1, ALOX5, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.022E-08 | 1.947E-07 | FLT3, PIM1, AKT1, MAPK1, PIK3R1, NFKB1, PPARD |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.075E-08 | 1.947E-07 | GSK3B, AR, AKT1, MAPK1, PIK3R1, TP53, NFKB1, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.467E-08 | 2.262E-07 | PLA2G1B, MAOA, GAA, ALOX15, AKR1B1, ALOX12, PYGL, CYP2C19, CYP3A4, TYR, CYP19A1, HSD17B10, PTGS1, CYP2C9, CYP2C8, HSD17B1, ALOX5, HSD17B2, CYP1A2, ALDH1A1, CYP1A1, ALPI, XDH |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.473E-08 | 4.589E-07 | SRC, AKT1, MAPK1, STAT6, PIK3R1, TP53, MMP9, NFKB1, TLR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 8.618E-08 | 9.965E-07 | GSK3B, KDR, AKT1, MAPK1, PIK3R1, PKN1, TP53, MET, PTK2, NFKB1, TLR2, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.233E-08 | 4.589E-07 | FLT3, AKT1, MAPK1, PIK3R1, TP53, MET, HIF1A |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.158E-08 | 1.947E-07 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 2.010E-07 | 2.065E-06 | CAMK2B, GSK3B, SRC, AKT1, MAPK1, PIK3R1, PTK2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 5.558E-07 | 5.141E-06 | GSK3B, SRC, KDR, AKT1, MAPK1, PIK3R1, MET, PTK2, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 4.099E-08 | 5.056E-07 | DAPK1, SRC, MMP2, MAPK1, MMP9, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 4.686E-07 | 4.563E-06 | SRC, KDR, AKT1, MAPK1, PIK3R1, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.333E-07 | 1.451E-06 | CYP2C9, CYP2C8, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 6.865E-07 | 5.521E-06 | CAMK2B, AKT1, MAPK1, PIK3R1, TP53, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 6.402E-07 | 5.521E-06 | CAMK2B, AKT1, MAPK1, PIK3R1, HIF1A, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.163E-06 | 8.606E-06 | AKT1, MAPK1, PIK3R1, TP53, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.607E-06 | 1.101E-05 | GSK3B, SRC, AKT1, MAPK1, PIK3R1, TP53, HIF1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.799E-06 | 1.189E-05 | CAMK2B, GSK3B, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.264E-06 | 8.993E-06 | GSK3B, SRC, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 3.305E-06 | 2.108E-05 | GSK3B, CXCR1, SRC, AKT1, MAPK1, PIK3R1, NFKB1, PTK2 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 6.865E-07 | 5.521E-06 | CYP2C9, CYP2C8, CYP1A2, ALDH1A1, CYP1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 9.810E-07 | 7.562E-06 | CYP2C9, CYP2C8, MAOA, CYP1A2, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 3.576E-06 | 2.205E-05 | GSK3B, AKT1, MAPK1, PIK3R1, PPARA, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 4.147E-06 | 2.475E-05 | GSK3B, CSNK2A1, AKT1, PIK3R1, TP53, NFKB1, TLR2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 9.168E-06 | 4.711E-05 | MMP2, PIM1, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 6.051E-06 | 3.392E-05 | AKT1, PPARG, PIK3R1, TP53, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.369E-05 | 6.664E-05 | PLA2G1B, KDR, AKT1, MAPK1, PIK3R1, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 8.169E-06 | 4.318E-05 | SRC, MMP2, AKT1, MAPK1, PIK3R1, MMP9 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.497E-05 | 6.922E-05 | MMP3, AKT1, MAPK1, PIK3R1, MMP9, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.420E-05 | 6.738E-05 | GSK3B, AKT1, PIK3R1, PYGL, PPARA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 7.219E-06 | 3.928E-05 | ALK, AKT1, MAPK1, PIK3R1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 4.987E-06 | 2.883E-05 | GSK3B, AKT1, MAPK1, PIK3R1, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.233E-05 | 9.606E-05 | ALOX5, AKT1, MAPK1, PIK3R1, NFKB1, TLR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.456E-05 | 1.033E-04 | ABCC1, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 5.389E-05 | 1.955E-04 | GSK3B, CSNK2A1, CDK1, AKT1, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 4.902E-05 | 1.814E-04 | CAMK2B, AKT1, MAPK1, PIK3R1, PPARA, NFKB1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.195E-05 | 5.977E-05 | GSK3B, AKT1, MAPK1, PIK3R1, TP53 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 5.841E-05 | 2.026E-04 | LMNA, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 5.914E-05 | 2.026E-04 | POLB, SRC, CDK1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.626E-05 | 7.163E-05 | AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 7.092E-05 | 2.386E-04 | SRC, KDR, AKT1, MAPK1, PIK3R1, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 9.209E-05 | 3.042E-04 | ABCC1, PIM1, CYP1B1, MAPK1, TP53, MMP9, MET, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.662E-05 | 1.048E-04 | AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.626E-05 | 7.163E-05 | AKT1, MAPK1, PIK3R1, MET, HIF1A |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.662E-05 | 1.048E-04 | GSK3B, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.095E-04 | 3.554E-04 | CDK1, AKT1, MAPK1, PIK3R1, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.662E-05 | 1.048E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.844E-05 | 1.096E-04 | CSNK2A1, SRC, MAPK1, MET, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.968E-04 | 5.810E-04 | CAMK2B, ACHE, AKT1, MAPK1, PIK3R1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 5.876E-05 | 2.026E-04 | AKT1, PIK3R1, TP53, NFKB1, PTK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.450E-04 | 4.545E-04 | AKT1, MAPK1, PIK3R1, NFKB1, TLR2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.450E-04 | 4.545E-04 | GSK3B, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.585E-04 | 4.808E-04 | AKT1, MAPK1, PIK3R1, NFKB1, TLR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 2.183E-04 | 6.310E-04 | CAMK2B, SRC, AKT1, MAPK1, NFKB1, TLR2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 3.053E-04 | 8.558E-04 | SRC, AKT1, MAPK1, PIK3R1, PTGS1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 3.171E-04 | 8.729E-04 | CAMK2B, AR, CDK1, MAPK1, IGF1R |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 4.388E-04 | 1.127E-03 | AKT1, MAPK1, PPARG, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 3.948E-04 | 1.029E-03 | CAMK2B, GSK3B, MAOA, AKT1, DRD4 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 8.080E-04 | 1.941E-03 | GSK3B, AKT1, PIK3R1, PPARA, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 6.121E-04 | 1.490E-03 | GSK3B, AKT1, MAPK1, PIK3R1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 5.555E-04 | 1.389E-03 | GSK3B, AKT1, MAPK1, PIK3R1, PYGL |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 6.121E-04 | 1.490E-03 | CAMK2B, GSK3B, CSNK2A1, TP53, PPARD |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.267E-03 | 2.950E-03 | AKT1, MAPK1, PIK3R1, ADRA2C, ADRA2A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 1.530E-03 | 3.331E-03 | POLB, GSK3B, AKT1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 1.558E-03 | 3.352E-03 | GSK3B, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 1.988E-03 | 4.227E-03 | CSNK2A1, CDK1, TP53, NFKB1, TLR2 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.275E-03 | 2.950E-03 | CAMK2B, SRC, ALOX12, PIK3R1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04916 | Melanogenesis | 1.375E-03 | 3.101E-03 | CAMK2B, GSK3B, MAPK1, TYR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 9.681E-04 | 2.296E-03 | CAMK2B, SRC, MMP2, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 1.426E-03 | 3.141E-03 | AKT1, MAPK1, PIK3R1, HIF1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 1.375E-03 | 3.101E-03 | PIK3R1, NFKB1, PTK2, TLR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 3.013E-03 | 6.264E-03 | AKT1, PPARG, PIK3R1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04922 | Glucagon signaling pathway | 1.426E-03 | 3.141E-03 | CAMK2B, AKT1, PYGL, PPARA |
| 09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 3.284E-03 | 6.750E-03 | GSK3B, MAPK1, MET, PTK2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.873E-03 | 7.622E-03 | AKT1, MAPK1, PIK3R1, IGF1R |
| 09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 2.519E-03 | 5.296E-03 | MMP2, PIK3R1, MMP9, PTK2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 5.132E-03 | 9.688E-03 | CXCR1, AKT1, MAPK1, PIK3R1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.512E-04 | 4.662E-04 | AKT1, PIK3R1, TSHR, PTGS1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.978E-04 | 5.810E-04 | AKT1, MAPK1, PIK3R1, HIF1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 5.418E-04 | 1.373E-03 | SRC, PIK3R1, MET, PTK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.209E-04 | 8.729E-04 | CXCR1, SRC, MET, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 3.394E-04 | 9.099E-04 | FABP3, PPARG, PPARA, PPARD |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 4.286E-03 | 8.347E-03 | AKT1, MAPK1, PIK3R1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 5.228E-03 | 9.770E-03 | MAPK1, NFKB1, TLR2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 4.649E-03 | 8.960E-03 | AKT1, PPARA, NFKB1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.838E-03 | 9.227E-03 | CA2, CYP3A4, ABCG2 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 3.613E-03 | 7.345E-03 | AKT1, PIK3R1, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.990E-05 | 1.506E-04 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 3.775E-03 | 7.509E-03 | SRC, MAPK1, NFKB1 |
| 09160 Human Diseases | 09162 Immune diseases | hsa05321 | Inflammatory bowel disease (IBD) | 3.775E-03 | 7.509E-03 | STAT6, NFKB1, TLR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 3.577E-04 | 9.453E-04 | MAPK1, PPARG, TP53 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 5.402E-03 | 9.994E-03 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.259E-04 | 6.429E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
